Related Experiment Videos
Gemifloxacin is effective in experimental pneumococcal meningitis
A Smirnov1, A Wellmer, J Gerber
1Department of Neurology, University of Göttingen, Göttingen, Germany.
Antimicrobial Agents and Chemotherapy
|February 19, 2000
Summary
Gemifloxacin effectively reduces Streptococcus pneumoniae bacterial titers in cerebrospinal fluid (CSF) in a rabbit meningitis model, comparable to ceftriaxone. Dexamethasone did not impact gemifloxacin
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Streptococcus pneumoniae meningitis is a serious infection.
- Novel antimicrobial agents are needed for effective treatment.
- Understanding drug efficacy in relevant models is crucial.
Purpose of the Study:
- To evaluate the efficacy of gemifloxacin in a rabbit model of Streptococcus pneumoniae meningitis.
- To compare gemifloxacin's activity with ceftriaxone.
- To assess the impact of dexamethasone coadministration on gemifloxacin's pharmacokinetics and activity.
Main Methods:
- A rabbit model of Streptococcus pneumoniae meningitis was utilized.
- Bacterial titers in cerebrospinal fluid (CSF) were measured.
- Serum and CSF concentrations of gemifloxacin were determined.
- The effect of dexamethasone on gemifloxacin levels and activity was assessed.
Main Results:
- Gemifloxacin (5 mg/kg/h) significantly reduced bacterial titers in CSF, comparable to ceftriaxone (10 mg/kg/h).
- Gemifloxacin achieved measurable serum and CSF concentrations.
- Coadministration of dexamethasone (1 mg/kg) did not alter gemifloxacin serum/CSF levels or its antibacterial activity.
Conclusions:
- Gemifloxacin demonstrates potent in vivo activity against Streptococcus pneumoniae meningitis in rabbits.
- Gemifloxacin presents a potential therapeutic option for bacterial meningitis.
- Dexamethasone does not interfere with gemifloxacin's efficacy in this model.